The Australasian Gastro-Intestinal Trials Group is conducting a clinical trial with Bionomics
(ASX:BNO) in combination with nivolumab.
The trial will enrol patients with advanced metastatic colorectal cancer at approximately 15 sites around Australia.
Biopharmaceutical company will enter phase II clinical trial of its cancer drug candidate, BNC105, in combination with Bristol-Myers Squibb’s nivolumab.
It's to test to see if the immune oncology drug can be used in combination with a vascular disrupting agent to treat patients that have exhausted all other options.
Shares in Bionomics
(ASX:BNO) are trading 6.1 per cent higher at 10 cents.
